Honkamp Krueger Financial Services Inc. grew its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 4.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,015 shares of the medical research company’s stock after purchasing an additional 46 shares during the period. Honkamp Krueger Financial Services Inc.’s holdings in Edwards Lifesciences were worth $237,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of EW. Nuveen Asset Management LLC grew its position in shares of Edwards Lifesciences by 8,278.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock valued at $730,013,000 after buying an additional 3,904,405 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in Edwards Lifesciences by 394.9% in the second quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock valued at $67,336,000 after acquiring an additional 290,838 shares during the period. Invesco Ltd. boosted its stake in Edwards Lifesciences by 16.1% in the second quarter. Invesco Ltd. now owns 1,094,610 shares of the medical research company’s stock valued at $202,218,000 after acquiring an additional 151,686 shares during the period. Morgan Stanley boosted its stake in Edwards Lifesciences by 16.3% in the second quarter. Morgan Stanley now owns 1,003,510 shares of the medical research company’s stock valued at $185,387,000 after acquiring an additional 140,533 shares during the period. Finally, Eaton Vance Management bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $24,759,000. Institutional investors own 80.74% of the company’s stock.
In other Edwards Lifesciences news, VP Catherine M. Szyman sold 2,500 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $227.19, for a total transaction of $567,975.00. Following the completion of the transaction, the vice president now directly owns 19,605 shares of the company’s stock, valued at approximately $4,454,059.95. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction on Friday, November 15th. The shares were sold at an average price of $242.38, for a total value of $5,538,383.00. In the last three months, insiders have sold 174,241 shares of company stock worth $40,929,955. 1.63% of the stock is owned by corporate insiders.
NYSE:EW opened at $236.79 on Thursday. The stock has a market cap of $49.23 billion, a price-to-earnings ratio of 44.70, a PEG ratio of 2.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.74 and a current ratio of 3.53. Edwards Lifesciences Corp has a 1 year low of $156.00 and a 1 year high of $247.64. The business has a fifty day moving average of $236.16 and a 200-day moving average of $222.92.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.19. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The company’s revenue was up 20.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.07 earnings per share. On average, equities research analysts predict that Edwards Lifesciences Corp will post 5.6 EPS for the current year.
A number of analysts have recently weighed in on EW shares. Piper Jaffray Companies raised their price target on Edwards Lifesciences from $255.00 to $262.00 and gave the stock an “overweight” rating in a report on Monday, December 9th. Wells Fargo & Co upped their price objective on Edwards Lifesciences from $262.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. UBS Group increased their target price on Edwards Lifesciences from $250.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, December 6th. ValuEngine cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $217.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, October 22nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Edwards Lifesciences has an average rating of “Buy” and an average target price of $239.42.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: Purposes and Functions of the Federal Reserve
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.